NeuroOne Medical Technologies Corporation Releases White Paper: Thin-Film Electrodes Show Potential for Transforming Neurosurgery

Less invasive, more cost-effective solution may enhance neurosurgery for people with neurological brain conditions, including epilepsy

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–#brainstimulation—NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from brain and spine-related neurological disorders, today announces the release of its white paper, “Thin-Film Electrodes Show Potential for Transforming Neurosurgery,” exploring recent advances in thin-film technology that may offer a less invasive, more cost-effective solution to enhance neurosurgery for people with brain conditions, including epilepsy, Parkinson’s disease, dystonia, essential tremors and pain management for failed back surgery syndrome. Including commentary from Kip Ludwig, Ph.D., Associate Professor of Biomedical Engineering Adjunct Faculty of Neurological Surgery, University of Wisconsin, the white paper points to the flexible thin-film substrate as having many benefits compared to existing technology that is currently used clinically.

“Fundamentally, this innovative, patented thin-film technology offers advantages over currently commercially available electrodes, including more efficient automated manufacturing processes,” says Dave Rosa, president and CEO, NeuroOne. “EVO Cortical Electrodes (EVO), the first FDA-cleared thin-film electrodes for recording, monitoring and stimulating brain tissue for up to 30 days, have demonstrated a reduction in the brain’s immunological response, potentially improving patient comfort and reducing signal artifacts.”

EVO may also reduce time for diagnosis to provide much-needed cost savings for hospitals and patients. In initial pre-clinical clinical testing, EVO demonstrated the ability to provide higher fidelity recordings, which may allow physicians to more precisely identify the brain tissue responsible for causing seizures. Because of its potential for minimally invasive placement, along with its single tail design, EVO may mean fewer post-procedure complications and may potentially reduce the risk of infection.

“I’m looking forward to seeing the NeuroOne thin-film electrode technology become widely available clinically,” says Dr. Ludwig. “The NeuroOne manufacturing process should be extensible to diverse areas in neuromodulation such as deep brain stimulation and spinal cord stimulation. One can imagine this platform technology soon being used to create patient specific electrode configurations to treat a host of diseases/disorders.”

Rosa adds, “Building and improving upon old and innovative technologies that have been in use for decades, this significant medical technology is poised to hit the market.”

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, pain management for failed back surgery syndrome and other related neurological disorders that may improve patient outcomes and reduce procedural costs. Visit https://www.n1mtc.com/.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the timing of the Company’s regulatory submissions, potential regulatory approval, commercialization of the technology, business strategy, market size, potential growth opportunities, plans for product applications and product development, future operations, future efficiencies, and other financial and operating information. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including our ability to raise additional funds, uncertainties inherent in the development process of our technology, delays in the manufacturing process, changes in regulatory requirements or decisions of regulatory authorities, , the size and growth potential of the markets for our technology, our ability to serve those markets, the rate and degree of market acceptance of our products, clinical trial patient enrollment, the results of clinical trials, future competition, the actions of third-party clinical research organizations, suppliers and manufacturers, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward‐looking statements speak only as of the date of this press release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.

“Caution: Federal law restricts this device to sale by or on the order of a physician.”

Contacts

Media:
Brittany Tedesco

CPR Communications

btedesco@cpronline.com
201.641.1911 x 14

Investor Relations Contact:

PCG Advisory, Inc.

Stephanie Prince

(646) 762-4518